Medicaid demands specialty pharmacy price transparency, penalizes non-disclosure

What it does

This bill requires the federal government to survey specialty pharmacy drug prices (mail-order, specialty-handling pharmacies) to establish accurate cost benchmarks for Medicaid reimbursement, separate from retail pharmacy surveys. States must require specialty pharmacies receiving Medicaid payments to respond to these surveys and disclose pricing information; non-compliance triggers civil penalties. The bill also funds oversight studies to examine how affiliated pharmacies (owned by pharmacy benefit managers or wholesalers) report costs differently than independent pharmacies, and appropriates $5 million for inspector general oversight and $9 million annually for survey operations.

Why we flagged it

The bill's core mechanism is a mandatory survey and disclosure regime for specialty pharmacy acquisition costs, paired with enforcement penalties and oversight funding. It is fundamentally a transparency and cost-control measure targeting a specific pharmacy sector within Medicaid, not a broad entitlement expansion or industry subsidy.

What the text implies

• Specialty pharmacies affiliated with pharmacy benefit managers (PBMs) face heightened scrutiny for cost-reporting disparities; this may pressure PBM-owned pharmacies to align pricing with independent competitors or face reputational/compliance risk.
• The bill explicitly prohibits states from using specialty pharmacy pricing data to set retail community pharmacy rates, creating a firewall; this protects retail pharmacies from downward pressure but may limit states' ability to benchmark reimbursement across pharmacy types.
• Survey non-response and non-compliance penalties apply to individual pharmacies and chains; specialty pharmacy chains may face cumulative penalties across multiple locations, creating compliance cost pressure.
• The $9 million annual appropriation for survey operations is open-ended ('each fiscal year thereafter'), creating a permanent budget commitment without sunset or review trigger.
• Guidance on pharmacy type indicators (due Jan 1, 2028) will determine which entities are subject to survey requirements; this regulatory discretion may affect mail-order and specialty-handling pharmacy definitions.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicaid beneficiaries and state programs benefit from more accurate drug-cost data, which can reduce overpayment for specialty drugs and improve reimbursement precision. The bill constrains specialty pharmacies' ability to obscure pricing through non-disclosure and penalizes non-compliance, reducing information asymmetry that has historically allowed inflated reimbursement claims. Oversight of affiliated-pharmacy cost reporting addresses a known mechanism by which pharmacy benefit managers may

Named in the bill

Department of Health and Human Services (HHS), Office of the Inspector General (OIG), Medicaid, Specialty pharmacies, Mail-order pharmacies, Pharmacy benefit managers (PBMs), State Medicaid agencies, Managed care entities

Where it stands

1 cosponsor: 1 Republicans.

• Sep 29, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 29, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.